Abivax to present at the 39th annual J.P. Morgan Healthcare Conference ahead of major clinical milestones
"We look forward to sharing this data in Q2 2021 and bringing ABX464 into phase 3 clinical testing for ulcerative colitis and phase 2b/3 testing for Crohn’s disease, for the benefit of the many patients suffering from devastating inflammatory bowel disease despite currently available treatments." Prof. Hartmut J. Ehrlich, M.D.
PARIS, December 21, 2020 – 6:30 p.m. (CET) – Abivax (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announced that Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 10:00 am to 10:40 am Eastern Time (4:00 pm to 4:40 pm Central European Time).
Prof. Hartmut J. Ehrlich, M.D., said: “The first half of 2021 is an exciting transformational period for Abivax as we will have three major value inflection points for our lead drug-candidate ABX464. We look forward to sharing this data in Q2 2021 and bringing ABX464 into phase 3 clinical testing for ulcerative colitis and phase 2b/3 testing for Crohn’s disease, for the benefit of the many patients suffering from devastating inflammatory bowel disease despite currently available treatments. We are proud to have the unique opportunity to share our ambitious prospects during the JPM conference being one of the four French companies invited together with Sanofi, Dassault Systèmes and Ipsen.”
During H1 2021, Abivax will report top-line data from three ongoing clinical trials of ABX464: 1) a phase 2b trial to treat ulcerative colitis (UC) (recruitment completed: 254 patients randomized); 2) a phase 2a trial to treat rheumatoid arthritis; and 3) a pivotal phase 2b/3 study to prevent progression of Covid-19 infection into severe forms of the disease, including acute respiratory distress syndrome (ARDS). Also, in 2021 Abivax intends to start pivotal phase 3 testing of ABX464 to treat UC and pivotal phase 2b/3 testing of ABX464 to treat Crohn’s disease (CD).
Should results of the phase 2b/3 study with ABX464 in Covid-19 be positive, Abivax will be seeking marketing approvals in the major markets in 2021, while it is preparing for the manufacturing scaling-up and potential commercialization of ABX464, in order to prevent the evolution of serious disease and death in Covid-19 infected high-risk patients. During 2020 Abivax secured EUR 84M in total financing, including an oversubscribed capital increase at market price of EUR 28M in October, with participation from top-tier U.S. and European specialist biotech investors, as well as EUR 20M in grants from Bpifrance, and EUR 36M in loans from Bpifrance, Kreos Capital and Société Générale. The Company has cash for operations until Q4 2021. Investors and other interested parties who will not participate in the JPM event are invited to access the live audio webcast of the presentation at https://www.abivax.com/events. An archived version of the webcast will be available under the same link for a limited period of time. The Abivax management will be available for 1:1 meetings at the conference through J.P. Morgan platform at https://events.jpmorgan.com.